DUBLIN – Bidding to become the second European firm to win a gene therapy approval, Glaxosmithkline plc filed a marketing authorization application (MAA) with the EMA for GSK2696273, a treatment for severe combined immunodeficiency syndrome associated with adenosine deaminase deficiency (ADA-SCID) in patients for whom bone marrow transplants are not possible.